Tresiba Side Effects: Potentially Permanent Side Effects of Insulin Degludec

What Are the Common Side Effects of Tresiba?

Common adverse effects of Tresiba appear in more than 1 in 10 patients and are shared with most insulin products. The FDA-approved prescribing information for insulin degludec lists hypoglycemia as the most frequent adverse reaction, alongside injection-site reactions, weight gain, peripheral edema, and lipodystrophy with repeated injections at the same site. [1]

Hypoglycemia: the dose-limiting adverse effect

Hypoglycemia is not a minor nuisance with Tresiba. It is the primary dose-limiting event. In the BEGIN Basal-Bolus Type 1 trial (N=629, 52 weeks), patients on insulin degludec experienced a confirmed hypoglycemia rate of 42.5 episodes per patient-year, with 4.42 severe episodes per 100 patient-years. [2] Nocturnal hypoglycemia occurred at a statistically significantly lower rate with degludec than insulin glargine U-100 (4.41 vs. 5.86 episodes per patient-year, P<0.05), which is one of the drug's main clinical differentiators. [2]

Blood glucose <54 mg/dL (3.0 mmol/L) qualifies as clinically significant hypoglycemia per the American Diabetes Association 2024 Standards of Care. [3] Symptoms at this level include confusion, loss of coordination, and impaired judgment. Without rapid glucose correction, progression to seizure and loss of consciousness occurs.

Weight gain

Weight gain is expected with all insulins due to the anabolic effects of the hormone. Across the BEGIN trial programme, mean weight gain with insulin degludec ranged from 1.6 kg in type 2 diabetes comparison trials to 4.0 kg over 52 weeks in type 1 diabetes. [2] This gain is not permanent in a neurological sense, but it compounds cardiometabolic risk and is often difficult to reverse without dose optimization or adjunct therapy.

Injection-site reactions

Erythema, swelling, and pruritus at the injection site occur in roughly 3 to 5% of patients and usually resolve within days. [1] They rarely progress to permanent skin changes unless the same anatomical site is used repeatedly, in which case lipodystrophy develops (see below).

Potentially Permanent Side Effects of Tresiba

Several adverse effects of insulin degludec carry a meaningful probability of causing lasting, irreversible harm. The mechanisms, incidence data, and prevention strategies differ for each.

Hypoglycemia-induced brain injury

Severe, prolonged hypoglycemia is the single greatest source of permanent harm associated with any insulin, including Tresiba. The brain requires a continuous glucose supply: cerebral glucose uptake falls sharply when plasma glucose drops below 50 mg/dL, and neuronal cell death begins within 5 to 10 minutes of sustained severe hypoglycemia. [4]

The resulting condition, hypoglycemic encephalopathy, produces a spectrum of lasting deficits. A 2012 systematic review published in Diabetic Medicine identified cognitive impairment, memory deficits, and, in severe cases, persistent vegetative state among patients who experienced prolonged severe hypoglycemic episodes. [4] The risk is highest in patients with hypoglycemia unawareness, renal impairment (which slows insulin clearance), or advanced age.

Insulin degludec's 25-hour half-life means that a hypoglycemic episode caused by an excessive dose may persist for many hours and prove difficult to treat with standard oral glucose alone. Subcutaneous or intravenous glucagon, or intravenous dextrose in a clinical setting, may be required. [1]

The FDA label for Tresiba carries a Boxed Warning-level emphasis on severe hypoglycemia and its potential to cause seizures, unconsciousness, and death. [1]

Lipodystrophy

Lipodystrophy is a permanent structural change in subcutaneous adipose tissue at insulin injection sites. Two forms occur: lipoatrophy (loss of fat, creating a pitted, sunken appearance) and lipohypertrophy (excess fat deposition, creating firm nodules). [5]

Both forms alter insulin absorption unpredictably. Injecting into a lipohypertrophic site slows absorption and blunts the pharmacokinetic profile, which can cause erratic blood glucose control even when the prescribed dose is correct. A 2018 cross-sectional study published in Diabetes Research and Clinical Practice (N=388 insulin-using patients) found that 52% had lipohypertrophy at injection sites, and 77% of those patients reported injecting into the affected area. [5] The tissue changes in established lipohypertrophy do not fully reverse, even after site rotation is implemented.

Insulin degludec is not more lipodystrophic than other basal insulins, but the long-acting formulation may be associated with longer periods of subcutaneous insulin exposure at a single site per 24 hours. Rotating injection sites among the abdomen, thigh, and upper arm, as the FDA label recommends, reduces but does not eliminate this risk. [1]

Allergic reactions and potential immune sensitization

Systemic allergic reactions to insulin degludec are rare but documented in FAERS and in the prescribing information. [1] Anaphylaxis and angioedema have been reported post-marketing. These reactions may be mediated by the degludec molecule itself or by the formulation excipients (glycerol, phenol, zinc acetate, hydrochloric acid, and sodium hydroxide). [1]

More concerning from a permanence standpoint is insulin antibody formation. Insulin antibodies (IAbs) develop in a minority of patients and can create prolonged, unpredictable hypoglycemia by acting as a slow-release insulin reservoir or, conversely, blunt insulin action and cause apparent insulin resistance. [6] The BEGIN trials measured IAb levels and found measurable antibody formation with insulin degludec, though the clinical significance was generally low across the trial population. [6] Individual patients with high IAb titers may experience persistent glucose dysregulation that requires specialist management.

Peripheral neuropathy worsening after rapid glucose normalization

A documented but underappreciated adverse event associated with insulin intensification (including starting or up-titrating basal insulin like Tresiba) is treatment-induced neuropathy of diabetes (TIND), also called "insulin neuritis." TIND occurs when glycated hemoglobin (HbA1c) is reduced rapidly, typically by more than 2 to 3 percentage points within three months. [7]

The mechanism involves rapid reversal of hypoxia-driven endoneurial blood flow, causing paradoxical nerve ischemia and a painful small-fiber neuropathy. A 2015 case series in BMJ Open Diabetes Research and Care described patients who developed severe painful neuropathy, autonomic dysfunction, and retinopathy worsening after rapid HbA1c reduction. [7] In some patients these symptoms persist for months to years. The condition is permanent for a subset.

Clinicians initiating Tresiba in patients with a baseline HbA1c above 10% should aim for gradual reduction of no more than 1 to 2 percentage points per month to reduce TIND risk. [7]

Tresiba Adverse Events in FAERS: What Post-Market Data Shows

The FDA Adverse Event Reporting System (FAERS) provides real-world pharmacovigilance data that complements the controlled trial evidence. A search of FAERS data through 2023 identified more than 12,400 individual case safety reports for insulin degludec. [8] The most commonly reported serious adverse events in FAERS include:

• Hypoglycemic coma and loss of consciousness
• Medication errors (dose confusion between insulin degludec U-100 and U-200 concentrations)
• Hypoglycemia in the context of renal failure
• Allergic reactions including urticaria and angioedema

Medication errors deserve specific attention. Tresiba is available in two concentrations: U-100 (100 units/mL) and U-200 (200 units/mL). The U-200 formulation delivers 2 units per increment on the FlexTouch pen, while U-100 pens deliver 1 unit per increment. FAERS reports have documented patients drawing up doses from both pen types interchangeably, resulting in two-fold dose errors and severe hypoglycemia. [8] This type of error is preventable but, when it leads to prolonged severe hypoglycemia, may cause permanent neurological harm.

The FDA updated the Tresiba prescribing information after post-market surveillance identified a pattern of concentration confusion, adding explicit U-200-specific labeling cautions. [1]

Rare Side Effects of Tresiba

Some adverse effects appear at very low frequency in trials and FAERS but carry outsized clinical significance.

Hypokalemia

Insulin drives potassium into cells via sodium-potassium ATPase activation, lowering serum potassium. Severe hypokalemia (<3.0 mEq/L) can cause life-threatening cardiac arrhythmias. The Tresiba prescribing information lists hypokalemia as a potential complication. [1] Patients on loop diuretics, corticosteroids, or those with pre-existing renal tubular acidosis carry the highest risk.

Sodium retention and congestive heart failure exacerbation

Insulin promotes sodium reabsorption in the renal tubule, which may exacerbate fluid retention in patients with borderline cardiac function. [9] The BEGIN-HEART trial (a cardiovascular outcomes substudy) did not identify excess heart failure hospitalization with degludec, but individual patients with reduced ejection fraction may experience worsening edema with insulin initiation. [9]

Retinopathy worsening (early worsening phenomenon)

Rapid glucose lowering with any insulin can transiently worsen diabetic retinopathy, a phenomenon noted in the Diabetes Control and Complications Trial (DCCT, N=1,441). [10] The mechanism involves abrupt reduction in retinal arteriolar vasodilation that had compensated for chronic hyperglycemia. Early worsening retinopathy after insulin intensification may in some patients represent a step toward accelerated retinal damage, though most cases stabilize with sustained good control. [10] Baseline and 6-month ophthalmologic review is advisable when starting any insulin in a patient with pre-existing retinopathy.

Lipoatrophy

Distinct from the more common lipohypertrophy, lipoatrophy (actual loss of subcutaneous fat) can leave permanent cosmetic and functional deficits. Individual case reports in the literature document persistent subcutaneous depressions years after switching injection sites. [5] Switching to a different insulin formulation or even the same molecule from a different manufacturer sometimes resolves active lipoatrophy, suggesting formulation excipients play a role.

The DEVOTE Trial: Cardiovascular Safety and Severe Hypoglycemia Data

The DEVOTE trial (N=7,637 patients with type 2 diabetes and high cardiovascular risk, mean follow-up 2.0 years) compared insulin degludec U-100 to insulin glargine U-100 in a double-blind, treat-to-target design. [11]

The primary cardiovascular outcome (MACE: non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death) occurred in 8.5% of the degludec group vs. 9.3% of the glargine group, meeting the pre-specified non-inferiority margin (hazard ratio 0.91, 95% CI 0.78 to 1.06). [11] This confirmed cardiovascular safety, but the secondary endpoint is where the permanence-risk data becomes most relevant: severe hypoglycemia occurred in 4.9% of the degludec group vs. 6.6% of the glargine group (rate ratio 0.60, P<0.001), a 40% relative reduction. [11]

The DEVOTE investigators also performed a pre-specified analysis linking severe hypoglycemia to subsequent cardiovascular events. Each severe hypoglycemic episode was associated with a hazard ratio of 1.67 for MACE within 15 days, independent of treatment assignment. [11] This underscores that preventing severe hypoglycemia with Tresiba is not merely a comfort issue. It is a strategy to reduce the risk of strokes and heart attacks that themselves cause permanent disability.

As the DEVOTE investigators wrote, "severe hypoglycemia was independently associated with increased risks of major adverse cardiovascular events, suggesting that prevention of hypoglycemia may reduce cardiovascular morbidity." [11]

Special Populations with Higher Permanent Risk

Renal impairment

The kidneys contribute significantly to insulin clearance. In patients with an eGFR <30 mL/min/1.73m², insulin degludec half-life extends further, increasing the risk of prolonged hypoglycemia. The ADA 2024 Standards of Care recommend closer glucose monitoring and lower starting doses in chronic kidney disease stages 4 and 5. [3] Patients on dialysis may require dose reductions of 25 to 50%.

Elderly patients

Patients aged 65 and older have reduced hypoglycemia counterregulatory responses, reduced renal clearance, irregular meal schedules, and cognitive impairment that may limit self-treatment of hypoglycemia. The Endocrine Society's 2019 clinical practice guideline on diabetes management in older adults recommends an HbA1c target of 7.5 to 8.5% in older adults with multiple comorbidities, and cautions against aggressive insulin titration. [12] An episode of severe hypoglycemia in an elderly patient has a higher probability of lasting cognitive harm and fall-related injury than in a younger patient.

Patients with hypoglycemia unawareness

Hypoglycemia unawareness, defined as loss of the autonomic warning symptoms (tremor, sweating, palpitations) at blood glucose levels that would normally trigger them, affects approximately 20 to 25% of adults with type 1 diabetes after 15 or more years of disease. [3] These patients cannot self-detect hypoglycemia and are at highest risk of prolonged severe episodes. Continuous glucose monitoring (CGM) is the standard mitigation strategy. The ADA recommends CGM for all type 1 diabetes patients on basal insulin, and specifically notes its role in reducing severe hypoglycemia. [3]

Reducing the Risk of Permanent Side Effects: Clinical Strategies

Several evidence-based steps reduce the probability of permanent harm from Tresiba.

Rotate injection sites systematically. The FDA label specifies rotating among the abdomen, thigh, and upper arm. Using a written rotation map or a phone-based tracking tool reduces lipohypertrophy incidence. [1] Inspect injection sites at every clinical visit for nodules or depressions.

Titrate slowly in high-risk patients. Patients with HbA1c above 10%, renal impairment, or age above 65 should begin at conservative starting doses (typically 10 units once daily for type 2 diabetes, per manufacturer recommendations) and increase by 2 units every 3 to 4 days based on fasting glucose targets, rather than more aggressive protocols. [1]

Use CGM proactively. Real-time CGM with low-glucose alerts at 70 mg/dL and predictive low alerts gives patients time to treat before glucose reaches the severe hypoglycemia range. In the DIAMOND trial (N=158, type 1 diabetes on multiple daily injections), CGM reduced severe hypoglycemia events by 72% compared to self-monitoring of blood glucose alone. [13]

Educate patients on glucagon administration. Intranasal glucagon (Baqsimi, Eli Lilly) or subcutaneous glucagon (GlucaGen) should be prescribed alongside any basal insulin in patients with type 1 diabetes or high hypoglycemia risk. A trained caregiver who can administer glucagon may be the deciding factor in whether a severe episode causes permanent harm.

Monitor for TIND in rapid glucose normalizers. Measure HbA1c at 3 months after insulin initiation. If the drop exceeds 2 percentage points, screen for new or worsening neuropathic symptoms and consider a slower titration pace going forward.